Status:
COMPLETED
Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
Brief Summary
This study aims to assess the value of combined treatment with RAD001 and erlotinib in patients with advanced Non Small Cell Lung Cancer treated only with chemotherapy as systemic therapy.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Age over 18 years
- Advanced Non Small Cell Lung Cancer which is not responding to chemotherapy treatment including either cisplatin or carboplatin
- Only 1-2 previous chemotherapy regimens for advanced disease
- More than 2 weeks from previous surgery, radiation or chemotherapy
- Ability to perform normal daily functions
- Exclusion criteria:
- Chronic steroid treatment
- Prior treatment with EGFR inhibitors
- Active bleeding conditions, skin conditions, gastrointestinal disorders, mouth ulcers, eye conditions or other severe medical conditions
- Other cancers within the past 2 years
- Pregnant or breastfeeding women Other protocol-defined inclusion/exclusion criteria may apply
Exclusion
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
248 Patients enrolled
Trial Details
Trial ID
NCT00456833
Start Date
June 1 2005
Last Update
December 21 2020
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Atlanta, Georgia, United States, 30322
2
Novartis Investigative Site
Chicago, Illinois, United States, 60637-1470
3
Novartis Investigative Site
Boston, Massachusetts, United States, 02115
4
Novartis Investigative Site
Rochester, Minnesota, United States, 55905